Trombogena

Trombogena is a term used to describe substances, conditions, or factors that promote thrombosis, the formation of a blood clot. In practice, it refers to anything that increases the likelihood of clot development by influencing the components of the coagulation system, platelets, or the vessel wall.

Mechanisms of action commonly involve the components of Virchow's triad: endothelial injury, abnormal blood flow (stasis or turbulence), and hypercoagulability. Endothelial damage can expose tissue factor and collagen, triggering the coagulation cascade. Platelets may become activated and aggregate at the site, while coagulation factors generate thrombin and stabilize a fibrin-rich clot. External stimuli such as inflammation, cancer, or foreign bodies can amplify these processes, making events more likely.

Examples of trombogena factors include genetic thrombophilias (such as Factor V Leiden, prothrombin G20210A mutation, or deficiencies of protein C or protein S), acquired conditions like cancer, pregnancy, obesity, prolonged immobilization, recent surgery or trauma, and the use of estrogen-containing medications. Local factors such as prosthetic heart valves, central venous catheters, or inflammatory sites can also be trombogênicos. The interplay between these factors influences whether a clot forms in veins or arteries, with venous clots often driven by hypercoagulability and arterial clots more associated with platelet activation and endothelial injury.

Clinical relevance centers on assessing thrombotic risk, diagnosis through symptoms, D-dimer testing when appropriate, and imaging to locate clots. Management focuses on treating the clot and reducing risk by anticoagulation or antiplatelet therapy, along with addressing underlying trombogênic factors and promoting risk-reducing measures.